Jun 3, 2019 - Many important drugs for the treatment of cancer were approved by the FDA from the period of May 21 2018 to May 14 2019. Of note is Tecentriq which was approved in March 2018 and Talzenna in October 2018, both for locally advanced or metastatic TNBC. However, in the case of Tecentriq, only tumors with the PD-L1 marker were likely to respond and for Talzenna, only women with a BRCA mutation are eligible for treatment. These criteria means that most women diagnosed with TNBC are still not able to access these treatments because PD-L1 expression and BRCA mutations are only found in small subsets of women with TNBC. As there are no targeted therapies available for most TNBC, it remains a major unmet medical need.
May 24, 2019 - Disappointing news has just been just released about the promising new immunotherapy drug pembrolizumab (Keytruda), that did not show any overall survival advantage over conventional chemotherapy treatment in women with metastatic TNBC. There remains limited options for women diagnosed with this aggressive type of breast cancer, therefore it is imperative we keep working towards an effective targeted therapy for TNBC.
Read more here
Mar 28, 2019 - Accelerated approval for the use of Tecentriq, an immunotherapy drug, in combination with chemotherapy was granted for use in a specific subset of women with locally advanced or metastatic TNBC, whose tumor expressed the marker PD-L1, and who could not undergo surgery. However, there is a large population of women with TNBC tumors that do not express PD-L1, therefore we need to keep working on developing a targeted therapy that will be able help more women with TNBC.
Oct 30, 2018 - A comprehensive forecast report by DelveInsight ( a business consultant & market research firm) into the future of the TNBC market from 2016 - 2027, shows that there is plenty of room for growth in the therapeutics field for this disease.
Read more about the report here
July 13, 2016 - Expert key opinion leader Dr. Deborah A. Lannigan from Vanderbilt University recently published "that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulated fewer effectors". She went on to mention that "based on overwhelming evidence that RSK is involved in a number of diseases that have high moralities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use". Read the abstract here
Forbes - August 1, 2016 - "Biotech has been one of the hottest sectors in the venture capital asset class over the past new years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has enabled a wave of well-funded biotechs to mature with a lower cost of capital than a decade ago."
January 6, 2016 - Many factors contribute to the rapid forecasted growth of the breast cancer treatment market over the next seven years. Along with epidemiological factors, the impact of therapeutic regimens involving multiple combination therapies will help drive growth.
May 27, 2015 - The latest annual report from the Canadian Cancer Society predicts that the number of cancer cases will rise by 40% in the next 15 years due to an aging and increasing population.